Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 4/20 | 0.50 |
| ▸ | NPC1 | O15118 | 3/20 | 0.50 |
| ▸ | ITK | Q08881 | 5/20 | 0.48 |
| ▸ | GSK3B | P49841 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.45 |
| ▸ | MAPT | P10636 | 4/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | HPGD | P15428 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | CASP3 | P42574 | 2/20 | 0.45 |
| ▸ | SENP8 | Q96LD8 | 2/20 | 0.45 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.45 |
| ▸ | SENP6 | Q9GZR1 | 2/20 | 0.45 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.45 |
| ▸ | KDR | P35968 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16756058 | 0.77 | PPARG (0.38) | CYP19A1ITKGAA | |
| SCHEMBL3741818 | 0.75 | RAB9A (0.49) | CYP19A1RAB9ANPC1ITKGSK3B | |
| SCHEMBL29631691 | 0.74 | RAB9A (0.74) | CYP19A1RAB9ANPC1ITKGSK3B | |
| SCHEMBL374022 | 0.74 | RAB9A (0.74) | CYP19A1RAB9ANPC1ITKGSK3B | |
| SCHEMBL543150 | 0.73 | RAB9A (0.47) | CYP19A1RAB9ANPC1ITKGSK3B | |
| SCHEMBL1781163 | 0.73 | RAB9A (0.55) | CYP19A1RAB9ANPC1ITKGSK3B | |
| SCHEMBL82498 | 0.71 | NPC1 (0.58) | RAB9ANPC1KDM4EMAPTALDH1A1 | |
| SCHEMBL5179280 | 0.71 | ITK (0.61) | CYP19A1RAB9ANPC1ITKGSK3B | |
| SCHEMBL30337474 | 0.71 | ITK (0.57) | CYP19A1RAB9ANPC1ITKGSK3B | |
| SCHEMBL2489128 | 0.71 | ITK (0.57) | CYP19A1RAB9ANPC1ITKGSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2203447-B1 | INHIBITORS OF THE INTERACTION BETWEEN MDM2 AND P53 | JANSSEN PHARMACEUTICA NV (BE) | 2012-02-29 | — | — | EP | claimed |
| US-5321153-A | Asymetric hydrogenation | MONSANTO COMPANY (US) | 1994-06-14 | — | — | US | claimed |
| EP-2029570-B1 | FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA SA (BE) | 2014-10-15 | — | — | EP | disclosed |
| US-8324204-B2 | Fused thiophene derivatives as kinase inhibitors | UCB PHARMA SA (BE) | 2012-12-04 | — | — | US | disclosed |
| US-20100305066-A1 | Fused Thiophene Derivatives as Kinase Inhibitors | UCB PHARMA S.A. (BE) | 2010-12-02 | — | — | US | disclosed |
| WO-2009122148-A1 | FUSED THIOPHENE AND THIAZOLE DERIVATIVES AS PI3K KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2009-10-08 | — | — | WO | disclosed |
| WO-2009071890-A1 | TRICYCLIC KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2009-06-11 | — | — | WO | disclosed |
| WO-2009071895-A1 | FUSED THIAZOLE AND THIOPHENE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2009-06-11 | — | — | WO | disclosed |
| EP-2029570-A1 | FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS | UCB Pharma S.A. (BE) | 2009-03-04 | — | — | EP | disclosed |
| WO-2007141504-A1 | FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2007-12-13 | — | — | WO | disclosed |
| US-4968698-A | FUNGICIDES, ANTIPROTOZOA AGENTS | BURROUGHS WELLCOME CO. (US) | 1990-11-06 | — | — | US | disclosed |
| EP-0170524-A2 | Nitrogen containing heterocyclic compounds | THE WELLCOME FOUNDATION LIMITED (GB) | 1986-02-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305066-A1 | Fused Thiophene Derivatives as Kinase Inhibitors | PIKFYVE, PI4KA, PIK3CA | CYP19A1 2478/4885RAB9A 713/4885NPC1 3855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.